Latest Breaking News On - Rare pediatric disease designations - Page 4 : comparemela.com

Cyprium Therapeutics, a Fortress Biotech Subsidiary

Cyprium Therapeutics, a Fortress Biotech Subsidiary
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesLindsaya rosenwaldTony plohorosJaclyn jaffeStepheng kalerNicole mccloskeyHuman developmentNational institutes of healthFortress biotech incEuropean medicines agencyZydus lifesciences ltdJude children research hospitalFred hutchinson cancer centerDevelopment agreementSecurities exchangeCyprium therapeutics inc

Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®

Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®
kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomChristian behrenbruchKyahn williamsonDouglas baumIsotherapeutics groupAustralian therapeutic goods administrationTelix pharmaceuticals limited disclosure committeeCorporate communicationsAustralian securities exchangePrnewswire telix pharmaceuticals limitedBiosciences incDrug administrationTelix pharmaceuticalsHealth canadaPharmaceuticals limited

QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee

Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and related conditions, has signed a non-binding term sheet (the “Term Sheet”) with Telix Pharmaceuticals (US) Inc., a subsidiary of Telix Pharmaceuticals Limited (ASX: TLX) (collectively, “Telix”) providing material terms for the acquisition of the Company by Telix by means of a merger (the “Acquisition”).

United statesNamrata chandChristian behrenbruchC richard piazzaHealth canadaTelix pharmaceuticals us incIsotherapeutics groupTelix pharmaceuticalsDrug administrationAustralian securities exchangeBiosciences incTelix pharmaceuticals limitedAustralian therapeutic goods administrationTerm sheetPre closing collaborationAdoption fee

Bloomsbury Genetic Therapies Celebrates its One Year Anniversary and Outlines Key Strategic and Operational Achievements since Launch

Bloomsbury Genetic Therapies Celebrates its One Year Anniversary and Outlines Key Strategic and Operational Achievements since Launch

City ofUnited kingdomDrug administrationRegulatory agencySeek foundationBloomsbury genetic therapiesUniversity college londonBloomsbury genetic therapies limitedHalting ornithineDopamine transporter deficiency syndromeScientific adviceUnited kingdom medicinesNiemann pick diseaseInfantile neuroaxonal dystrophyOrphan drug designationsRare pediatric disease designations

Telix Pharmaceuticals Limited: Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®

Telix Pharmaceuticals Limited: Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesKyahn williamsonDouglas baumChristian behrenbruchTelix pharmaceuticalsHealth canadaDrug administrationCorporate communicationsPrnewswire telix pharmaceuticals limitedBiosciences incTelix pharmaceuticals limited disclosure committeeAustralian therapeutic goods administrationIsotherapeutics groupAustralian securities exchangePharmaceuticals limited